Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30593380 | 1.00 | IMPDH2 (0.36) | IMPDH2TNFKDM4EALDH1A1NPC1 | |
| SCHEMBL1234101 | 0.83 | ACHE (0.41) | IMPDH2MAPT | |
| SCHEMBL30901027 | 0.80 | HTT (0.51) | IMPDH2TNFKDM4EALDH1A1NPC1 | |
| SCHEMBL20299238 | 0.77 | LATS1 (0.49) | KDM4EALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL14344413 | 0.76 | KMT2A (0.50) | TNFKDM4EALDH1A1NPC1HPGD | |
| SCHEMBL31212711 | 0.76 | EGFR (0.42) | IMPDH2ALDH1A1GAAHTTJAK2 | |
| SCHEMBL2880111 | 0.72 | JAK2 (0.36) | IMPDH2TNFKDM4EALDH1A1NPC1 | |
| SCHEMBL29389300 | 0.71 | MAOA (0.56) | KDM4EALDH1A1PKMHPGDRAB9A | |
| SCHEMBL92707 | 0.71 | MAOA (0.56) | KDM4EALDH1A1PKMHPGDRAB9A | |
| SCHEMBL1234859 | 0.71 | PDE4A (0.55) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-09-18 | — | — | US | disclosed |
| WO-2025096494-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12173001-B1 | Pyrido[3,4-e][1,2,4]triazolo[4,3-c]pyrimidines as CK2 inhibitors | King Faisal University (SA) | 2024-12-24 | — | — | US | disclosed |
| EP-4444289-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-11987581-B1 | Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-2-carboxylic acids as CK2 inhibitors | King Faisal University (SA) | 2024-05-21 | — | — | US | disclosed |
| US-11964974-B1 | Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-3-carboxylic acids as CK2 inhibitors | King Faisal University (SA) | 2024-04-23 | — | — | US | disclosed |
| CN-116472047-A | Arylamine derivative, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2023107592-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107592-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023078241-A1 | AROMATIC AMINE DERIVATIVES AND PREPARATION METHOD AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023078241-A1 | AROMATIC AMINE DERIVATIVES AND PREPARATION METHOD AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2023-05-11 | — | — | WO | disclosed |
| EP-4161926-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Yumanity Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987581-B1 | Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-2-carboxylic acids as CK2 inhibitors | CDK2, CSNK2A2, CSNK2A1 | IMPDH2 2592/4885TNF 737/4885KDM4E 2699/4885 |
| US-11964974-B1 | Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-3-carboxylic acids as CK2 inhibitors | CDK2, CSNK2A3, CSNK2A1 | IMPDH2 2881/4885TNF 725/4885KDM4E 2763/4885 |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | IMPDH2 293/4885TNF 4744/4885KDM4E 3908/4885 |
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | IMPDH2 293/4885TNF 4744/4885KDM4E 3908/4885 |
| US-12173001-B1 | Pyrido[3,4-e][1,2,4]triazolo[4,3-c]pyrimidines as CK2 inhibitors | CDK2, CKS2, TK1 | IMPDH2 3291/4885TNF 1131/4885KDM4E 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.